Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117968 | 0.82 | ELANE (1.00) | ELANEMAPTMEN1RAB9AKMT2A | |
| SCHEMBL692229 | 0.80 | ELANE (0.66) | ELANEMEN1RAB9AKMT2ATDP1 | |
| SCHEMBL3539033 | 0.79 | ELANE (0.70) | ELANEMEN1KMT2A | |
| SCHEMBL1812732 | 0.79 | ELANE (0.70) | ELANEMEN1KMT2A | |
| SCHEMBL31000399 | 0.79 | ELANE (0.70) | ELANEMEN1KMT2A | |
| SCHEMBL4123057 | 0.79 | ELANE (0.70) | ELANEMEN1KMT2A | |
| SCHEMBL12758386 | 0.79 | ELANE (0.70) | ELANEMAPTHSD17B10MEN1RAB9A | |
| SCHEMBL12847193 | 0.79 | ELANE (0.70) | ELANEMEN1RAB9AKMT2A | |
| SCHEMBL3541523 | 0.79 | ELANE (0.70) | ELANEMAPTMEN1KMT2ATDP1 | |
| SCHEMBL757536 | 0.79 | ELANE (0.72) | ELANEMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541488-B2 | Formed resin article and polymer film | FUJIFILM CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8541488-B2 | Formed resin article and polymer film | FUJIFILM CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20110186791-A1 | ULTRAVIOLET ABSORBENT COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110186791-A1 | ULTRAVIOLET ABSORBENT COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110092619-A1 | FORMED RESIN ARTICLE AND POLYMER FILM | FUJIFILM CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110092619-A1 | FORMED RESIN ARTICLE AND POLYMER FILM | FUJIFILM CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-7897761-B2 | Heterocyclic compound | FUJIFILM CORPORATION (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897761-B2 | Heterocyclic compound | FUJIFILM CORPORATION (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110024701-A1 | Ultraviolet Absorbent Composition | FUJIFILM CORPORATION (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110024701-A1 | Ultraviolet Absorbent Composition | FUJIFILM CORPORATION (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2272935-A1 | ULTRAVIOLET ABSORBENT COMPOSITIONS | FUJIFILM Corporation (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100004439-A1 | Heterocyclic Compound | FUJIFLM CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004439-A1 | Heterocyclic Compound | FUJIFLM CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | ELANE 1479/4885MAPT 4345/4885HSD17B10 2200/4885 |
| US-20100004439-A1 | Heterocyclic Compound | PTGER1, CYP1A1, ALOX12 | ELANE 1343/4885MAPT 4807/4885HSD17B10 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.